Correlation Between Arcus Biosciences and Editas Medicine

Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arcus Biosciences and Editas Medicine, you can compare the effects of market volatilities on Arcus Biosciences and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Editas Medicine.

Diversification Opportunities for Arcus Biosciences and Editas Medicine

0.21

Correlation Coefficient

Arcus Biosciences  Editas Medicine

Modest diversification

The 3 months correlation between Arcus and Editas is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Editas Medicine go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Editas Medicine

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 0.48 times more return on investment than Editas Medicine. However, Arcus Biosciences is 2.07 times less risky than Editas Medicine. It trades about 0.14 of its potential returns per unit of risk. Editas Medicine is currently generating about -0.41 per unit of risk. If you would invest  1,456  in Arcus Biosciences on September 25, 2024 and sell it today you would earn a total of  135.00  from holding Arcus Biosciences or generate 9.27% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Arcus Biosciences  vs.  Editas Medicine

Arcus Biosciences

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Arcus Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Arcus Biosciences may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Editas Medicine

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Arcus Biosciences and Editas Medicine

The main advantage of trading using opposite Arcus Biosciences and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.

The idea behind Arcus Biosciences and Editas Medicine pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.